Bristol Myers Squibb closes immuno-oncology, cell therapy-focused Redwood City site
fiercebiotech.com/biotech/bms-closes-immuno-oncology-and-cell-therapy-focused-redwood-city-site
One of Chris Boerner’s first tours as the new CEO of Bristol Myers Squibb was of a 256,000 square-foot research facility in the Bay Area concentrated on the tumor microenvironment.
But months later, that Redwood City site is closing as part of a much-wider $1.5 billion-dollar restructuring effort. BMS is consolidating the work at a nearby site in Brisbane less than 20 miles…
This story appeared on fiercebiotech.com, .